Dr. Diamond has been involved in diagnostics and companion therapeutics for the last fifteen years. Dr. Diamond originated the ideas, which later developed into several marketed products, of 1) using software to combine multiple molecular markers together to determine a clinical outcome of interest; and 2) using non-molecular factors in conjunction with molecular markers to deliver a much more accurate predictive score for tumor aggressiveness.

Dr. Traugott has more than 20 years of biotech/pharma experience serving as Medical Director at Glaxo Wellcome, including being a member of Glaxo Wellcome’s International Medical Board. Dr. Traugott served as Manager, Clinical Research (Europe) at Genentech and led the Phase I-III clinical trials in Europe, including the development of Herceptin. He also served as Associate Director of Medical Oncology & Immunology at Knoll Pharmaceutical.

Prior to joining Prediction Sciences, Dr. Hiere was a senior neurologist at the Salk Institute in La Jolla, CA.

Dr. Sobel has spent over 10 years working in the emerging field of biosimilars and received market approval for the first three biosimilar drugs in the EU. He has 30 years of drug development experience with firms such as Merck, BioPartners, and Roche. As CSO of BioPartners, he led and managed the submission of the first biosimilar ever filed. The second biosimilar product, human growth hormone, resulted in successful marketing authorization.

Dr. Man oversees diagnostic test development and commercialization as well as reimbursement strategy for the company. Previously, Dr. Man successfully commercialized two diagnostics, including the Company's Insight Dx breast cancer diagnostic licensed to Clarient, a GE Healthcare company.